

# **Validation of an AI-based solution for breast cancer risk stratification using routine digital histopathology images**

Abhinav Sharma<sup>1</sup>, Sandy Kang Lövgren<sup>5</sup>, Kajsa Ledesma Eriksson<sup>5</sup>, Yinxu Wang<sup>5</sup>, Stephanie Robertson<sup>2</sup>, Johan Hartman<sup>2,3,4</sup>, Mattias Rantalainen<sup>1,4</sup>

<sup>1</sup>. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

<sup>2</sup>. Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden

<sup>3</sup>. Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden

<sup>4</sup>. MedTechLabs, BioClinicum, Karolinska University Hospital, Solna, Sweden

<sup>5</sup>. Stratipath AB, Solna, Sweden

**Corresponding author:** Mattias Rantalainen

**Email:** mattias.rantalainen@ki.se

**Table 1:** Baseline characteristics of the cohorts from two different hospitals in Sweden.

	<b>CHIME breast KS Solna (N=1542)</b>	<b>SCAN-B (N=933)</b>	<b>Overall (N=2475)</b>
<b>Age</b>			
Mean (SD)	61.6 (12.3)	65.5 (12.3)	63.0 (12.5)
Median [Min, Max]	63.0 [29.0, 94.0]	70.0 [30.0, 95.0]	65.0 [29.0, 95.0]
<b>Tumor size</b>			
<20mm	1043 (67.6%)	620 (66.5%)	1663 (67.2%)
>=20mm	486 (31.5%)	302 (32.4%)	788 (31.8%)
Missing	13 (0.8%)	11 (1.2%)	24 (1.0%)
<b>Lymph node status</b>			
Negative	1105 (71.7%)	646 (69.2%)	1751 (70.7%)
Positive	311 (20.2%)	260 (27.9%)	571 (23.1%)
Missing	126 (8.2%)	27 (2.9%)	153 (6.2%)
<b>NHG</b>			
1	302 (19.6%)	170 (18.2%)	472 (19.1%)
2	894 (58.0%)	527 (56.5%)	1421 (57.4%)
3	346 (22.4%)	236 (25.3%)	582 (23.5%)
<b>ER status</b>			
Negative	165 (10.7%)	87 (9.3%)	252 (10.2%)
Positive	1370 (88.8%)	842 (90.2%)	2212 (89.4%)
Missing	7 (0.5%)	4 (0.4%)	11 (0.4%)
<b>HER2 status</b>			
Negative	1349 (87.5%)	850 (91.1%)	2199 (88.8%)
Positive	151 (9.8%)	70 (7.5%)	221 (8.9%)
Missing	42 (2.7%)	13 (1.4%)	55 (2.2%)
<b>PFS (in years)</b>			
Mean (SD)	6.27 (2.53)	5.24 (2.24)	5.88 (2.47)
Median [Min, Max]	6.49 [0.153, 10.8]	5.23 [0.115, 10.2]	6.00 [0.115, 10.8]
<b>PFS status</b>			

0	1461 (94.7%)	902 (96.7%)	2363 (95.5%)
1	81 (5.3%)	31 (3.3%)	112 (4.5%)

---

NHG=Nottingham histological grade, ER=oestrogen receptor, HER2=human epidermal growth factor receptor 2, PFS = Progression-free Survival.